GUTS vs VKTX
GUTS: Fractyl Health is developing innovative procedural and gene therapy treatments aiming to address the root causes of obesity and type 2 diabetes. VKTX: A clinical-stage biopharmaceutical company developing next-generation dual GLP-1/GIP receptor agonists for the treatment of obesity and metabolic disorders.
Side-by-side fundamentals
| Metric | GUTS | VKTX | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $1.33 | $26.71 | |
| Market cap | $18M | $3.1B | |
| ROE FY2025, SEC XBRL | n/a | -56.3% | |
| ROA FY2025, SEC XBRL | -116.1% | -50.2% | VKTX higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.00 | 1.50 | |
| 1-year return as of 2026-10-20 close | -92.0% | -20.9% | VKTX higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.